Soy claims
This article was originally published in The Tan Sheet
Executive Summary
Solae Company's petition for health claims that soy protein-based foods may reduce the risk of certain types of cancer is being reviewed by FDA, the St. Louis based firm announced April 16. The petition cites 58 studies supporting the relationships, Solae says. The DuPont/Bunge joint venture is "looking forward to the agency's evaluation"...
You may also be interested in...
Soy petition withdrawal
The Solae Company is formally withdrawing from further consideration the qualified health claim petition linking soy protein consumption to prevention of cancer, the company confirms in a recent letter to the agency. "The nutrition science pertaining to the health benefits of soy protein is substantial and continues to evolve," and "serves as a catalyst for futher scientific investigation," Solae states. The firm has "closely monitored recent FDA actions with respect to certain qualified health claims. With the benefit of this information, the Solae Company respectifully reserves the option to resubmit a qualified health claim petition centering on soy protein and cancer prevention in the future." The firm also is "most appreciative of the deliberate fashion in which FDA reviewed" its petition, which it announced was under review in April 2004 (1"The Tan Sheet" April 19, 2004, In Brief)...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.